| Model Number |
EVOLUTPRO-29-US |
| Medical Device Problem Codes |
Calcified (1077); Gradient Increase (1270); Device Stenosis (4066)
|
| Health Effect - Clinical Codes |
Mitral Valve Insufficiency/ Regurgitation (4451); Tricuspid Valve Insufficiency/ Regurgitation (4453); Insufficient Information (4580)
|
| Date of Event |
11/21/2025
|
|
Type of Reportable Event
|
Serious Injury
|
|
Event or Problem Description
|
|
It was reported approximately eight years following the implant of this 29mm transcatheter aortic bioprosthetic valve (tav), valve failure was reported.The primary mode of valve failure was structural valve deterioration: predominant aortic stenosis (as) with severe hemodynamic valve deterioration.This was characterized by an increase in mean gradient of >=20mm hg from baseline and a mean gradient of >=30mm hg.The patient was enrolled in a clinical study with existing, baseline valve failure to determine whether a redo-tav replacement procedure, tav-in-tav, was appropriate.No patient symptoms prior to were reported as a result of this event.
|
| |
|
Additional Manufacturer Narrative
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Additional Manufacturer Narrative
|
|
Updated data: b1.B2.B5.B6.H1.Additional codes.Corrected data: b3.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
Additional information was received that approximately two and a half months later, a tav-in-tav was performed using a non-medtronic valve.
|
| |
|
Additional Manufacturer Narrative
|
|
Corrected data: b6, h6.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Search Alerts/Recalls
|